Public Market Listing
Live quotes, historical charts, and market capitalization for Idorsia Pharmaceuticals are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Aprocitentan(Tryvio) | Approved | Endothelin receptor (ETA/ETB, dual)Small molecule | Hypertension |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (2)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $73M | — | $119M | $59M | report ↗ |
View 1 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $152M | $58M | $91M | — | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $266M | $123M | $112M | $135M | report ↗ |
Idorsia reported 2025 revenue of $266.47M, up 107.6% YoY, with R&D spend of $122.99M, down 24.8% YoY. Cash and equivalents stood at $112.34M, while net income or loss was not disclosed; the quarterly net burn was $135.04M.
For 2026, management guided to QUVIVIQ sales of CHF 200M, non-GAAP operating expenses of approximately CHF 330M, and a non-GAAP operating loss of CHF 120M. Pipeline developments include an expected Q2 2026 Phase 2 readout for daridorexant in pediatric insomnia, FDA alignment on the registrational program for lucerastat in Fabry disease, and advancing immunology programs including a CCR6 antagonist in psoriasis. Key disclosed events include QUVIVIQ 2025 global net sales of CHF 134M, JERAYGO approvals in the EU, UK, Switzerland, and Canada, progressing partnership discussions for TRYVIO/JERAYGO, and a 2025 debt restructuring.